Health and Healthcare

Gilead Sciences : GILD

All Gilead Sciences Articles

734 Articles

Trey Thoelcke | May 11, 2017 at 11:40 AM EDT

Why Big Pharma Is Not at Fault for Record Drug Spending

With prescription drug spending breaking new records almost every year now, people like to blame Big Pharma and use it…

Chris Lange | May 10, 2017 at 10:40 AM EDT

Major Biotech Short Interest Remains Mixed

The April 28 short interest data have been compared with the previous report, and moves in the selected biotech stocks…

Jon C. Ogg | May 3, 2017 at 11:10 AM EDT

Gilead Faces Serious Conundrum: Value Trap vs Real Value

Many value investors have flocked to Gilead Sciences as the world's top biotech stock now that it is valued at…

Jon C. Ogg | May 2, 2017 at 7:55 AM EDT

Value or Value Trap: Meet the 21 S&P 500 Stocks Valued Under 10 Times Earnings

As of the start of May of 2017, just 21 members of the S&P 500 Index were valued at less…

Chris Lange | Apr 26, 2017 at 9:40 AM EDT

Short Sellers Grow More Selective on Major Biotechs

The April 13 short interest data have been compared with the previous report, and moves in the selected biotech stocks…

Lee Jackson | Apr 15, 2017 at 9:20 AM EDT

Analysts See 10 Companies Beating Expectations This Earnings Season

With earnings starting to really snowball next week, and a market that seems to be teetering somewhat due to high…

Chris Lange | Apr 12, 2017 at 9:10 AM EDT

Short Sellers Back Off Major Biotechs

The March 31 short interest data have been compared with the previous report, and short interest decreased in most of…

Lee Jackson | Apr 10, 2017 at 9:50 AM EDT

Jefferies Thinks 3 Red-Hot Biotech Stocks Can Beat Q1 Estimates

A massive new Jefferies research report reminds investors that as a rule the first quarter is traditionally slower for biotechnology…

Chris Lange | Mar 27, 2017 at 10:30 AM EDT

Short Interest Pulls Back in Major Biotechs

The health care sector in general has rallied since Trump took over the presidency, but now that his repeal of…

Chris Lange | Mar 25, 2017 at 9:15 AM EDT

How Health Care Stocks Responded to the Shelved Health Care Bill

24/7 Wall St. has taken a look at a few companies within the health care sector that might have seen…

Lee Jackson | Mar 20, 2017 at 9:50 AM EDT

Jefferies Has 4 Red-Hot Biotech and Pharmaceutical Stocks to Buy Now

These are four top stocks to buy in a sector that has much more value than many on Wall Street.…

Chris Lange | Mar 13, 2017 at 10:35 AM EDT

What a Combined Gilead and Incyte Would Look Like

Gilead Sciences has long been in need of a catalyst to move its business, and a lot of investors and…

Jon C. Ogg | Mar 13, 2017 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: AIG, Boeing, GameStop, Gilead, Starbucks, CIGNA, Ciena, Ferrari and Many More

The top analyst upgrades, downgrades and initiations seen on Monday include AIG, Boeing, GameStop, Gilead Sciences, Starbucks, CIGNA, Ciena and…

Chris Lange | Mar 10, 2017 at 10:30 AM EST

Major Biotechs See a Retreat in Short Interest

The February 28 short interest data have been compared with the previous report, and short interest decreased in most of…

Jon C. Ogg | Mar 9, 2017 at 8:45 AM EST

Top Analyst Upgrades and Downgrades: American Express, Amgen, Encana, Gilead, Tesla and Many More

The top analyst upgrades, downgrades and initiations seen on Thursday include American Express, Amgen, Encana, Gilead Science and Tesla.

1 … 20 21 22 23 24 … 49

Gilead Sciences : GILD

All Gilead Sciences Articles

Why Big Pharma Is Not at Fault for Record Drug Spending

Major Biotech Short Interest Remains Mixed

Gilead Faces Serious Conundrum: Value Trap vs Real Value

Value or Value Trap: Meet the 21 S&P 500 Stocks Valued Under 10 Times Earnings

Short Sellers Grow More Selective on Major Biotechs

Analysts See 10 Companies Beating Expectations This Earnings Season

Short Sellers Back Off Major Biotechs

Jefferies Thinks 3 Red-Hot Biotech Stocks Can Beat Q1 Estimates

Short Interest Pulls Back in Major Biotechs

How Health Care Stocks Responded to the Shelved Health Care Bill

Jefferies Has 4 Red-Hot Biotech and Pharmaceutical Stocks to Buy Now

What a Combined Gilead and Incyte Would Look Like

Top Analyst Upgrades and Downgrades: AIG, Boeing, GameStop, Gilead, Starbucks, CIGNA, Ciena, Ferrari and Many More

Major Biotechs See a Retreat in Short Interest

Top Analyst Upgrades and Downgrades: American Express, Amgen, Encana, Gilead, Tesla and Many More

Goldman Sachs Just Made 4 Bold Calls: 2 Sells, 1 Buy, and a $2,159 Price Target On This Popular Stock

Palantir CEO: “Something Has Gone Completely Wrong” With OpenAI and Anthropic

Pay for Daycare With Pre-Tax Dollars. Most Parents Leave Thousands on the Table Every Year

Pay for Daycare With Pre-Tax Dollars. Most Parents Leave Thousands on the Table Every Year

The Aircraft Loophole That Lets Any Business Erase Millions in One Tax Year

Goldman Sachs Just Made 4 Bold Calls: 2 Sells, 1 Buy, and a $2,159 Price Target On This Popular Stock

Palantir CEO: “Something Has Gone Completely Wrong” With OpenAI and Anthropic

Gilead Sciences : GILD

All Gilead Sciences Articles

Why Big Pharma Is Not at Fault for Record Drug Spending

Major Biotech Short Interest Remains Mixed

Gilead Faces Serious Conundrum: Value Trap vs Real Value

Value or Value Trap: Meet the 21 S&P 500 Stocks Valued Under 10 Times Earnings

Short Sellers Grow More Selective on Major Biotechs

Analysts See 10 Companies Beating Expectations This Earnings Season

Short Sellers Back Off Major Biotechs

Jefferies Thinks 3 Red-Hot Biotech Stocks Can Beat Q1 Estimates

Short Interest Pulls Back in Major Biotechs

How Health Care Stocks Responded to the Shelved Health Care Bill

Jefferies Has 4 Red-Hot Biotech and Pharmaceutical Stocks to Buy Now

What a Combined Gilead and Incyte Would Look Like

Top Analyst Upgrades and Downgrades: AIG, Boeing, GameStop, Gilead, Starbucks, CIGNA, Ciena, Ferrari and Many More

Major Biotechs See a Retreat in Short Interest

Top Analyst Upgrades and Downgrades: American Express, Amgen, Encana, Gilead, Tesla and Many More

Goldman Sachs Just Made 4 Bold Calls: 2 Sells, 1 Buy, and a $2,159 Price Target On This Popular Stock

Palantir CEO: “Something Has Gone Completely Wrong” With OpenAI and Anthropic

Pay for Daycare With Pre-Tax Dollars. Most Parents Leave Thousands on the Table Every Year

Featured Reads

Pay for Daycare With Pre-Tax Dollars. Most Parents Leave Thousands on the Table Every Year

The Aircraft Loophole That Lets Any Business Erase Millions in One Tax Year